Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Embracing Rival Programs, Juno Ventures Forth With Talk Of Cancer Cure

Executive Summary

The richly funded start-up is an unlikely collaboration between rival oncology research centers, both with immunotherapy programs that require complicated cell therapy processes. Coming together under one roof doesn’t mean the competition has ended.

You may also be interested in...



Biopharma Dealmaking Quarterly Statistics, Q4 2013

Biopharma financing totaled $6.4 billion, a 39% increase over Q3. Twenty-three M&As were completed with a combined potential value of $19.8 billion, and there were 103 biopharma alliances totaling $2.5 billion in potential pre-commercialization value, down 25% from the previous quarter.

Juno Therapeutics Enters Battle Over CAR Cancer Immunotherapy Technology

University of Pennsylvania seeks court order that its cancer immunotherapy does not infringe St. Jude’s patent; Juno, which licensed the patent for the potential leukemia treatment, has joined the settlement talks.

A New Industry-Academic Model: Novartis And Penn Make A Splash In Cancer Immunotherapy

Novartis’ deal with the University of Pennsylvania around cancer immunotherapies based on chimeric antigen receptor technologies developed in the lab of Penn’s Carl June comes at an opportune time. The Big Pharma is fighting to preserve its number two ranking in oncology and Penn’s high-profile, albeit much smaller, alliance with AstraZeneca in neurodegenerative disease is winding down.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055793

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel